1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
65151E0604B7ED76F652583DD001ECFF6
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/lifecycle-management-excellence-success-factors-barriers-lessons-learned-key-strategies-maximize-potential-mature-brands?OpenDocument
18
19OpenDocument
2054.198.246.164
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Brand Management and Product Leadership » Lifecycle Management

Lifecycle Management Excellence: Success Factors, Barriers & Lessons Learned in Using Key Strategies to Maximize Potential of Mature Brands

ID: 5554


Features:

10 Info Graphics

15 Data Graphics

310+ Metrics


Pages/Slides: 36


Published: 2019


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Lifecycle Management Excellence: Success Factors, Barriers & Lessons Learned in Using Key Strategies to Maximize Potential of Mature Brands”

STUDY OVERVIEW

With expiring patents & thin product pipelines, pharmaceutical and medical device companies are increasingly focused on lifecycle management strategies to extend the commercial life of their mature products. However, some of the lifecycle management strategies employed successfully in the past are losing traction due to current regulatory and cost pressures.

Best Practices, LLC undertook this benchmarking research to identify winning lifecycle management (LCM) strategies for mature brands. In particular, this study highlights the success factors, lessons learned and barriers to maximizing the potential of a mature brand.

Brand management and marketing leaders can refer to this research to execute successful lifecycle management strategies to extend the commercial life of pharmaceutical and medical device products and overcome the barriers encountered while implementing these strategies.

KEY TOPICS

  • Success rates of different strategies that leading companies have used to maximize mature-brand value
  • Regulatory barriers encountered with using each strategy
  • Lessons learned in using lifecycle management strategies to optimize the life of a pharmaceutical brand

KEY METRICS
  • What are the three most important factors of success in winning a lifecycle extension or maximizing the potential of a mature brand?
  • What barriers (if any) might prevent you from choosing each of the listed strategies to grow or extend a mature product?
  • Given the current health care reform environment, politics, mature drug shortages and other regulatory issues, do you expect any strategies that you have used successfully in the past to become ineffective or unusable within the next 12-24 months?
  • What lessons have you learned about using Lifecycle Management strategies to optimize the life of a pharmaceutical brand?

SAMPLE KEY FINDINGS
  • Barriers in Implementing Strategy: More than 90% of the companies encounter barriers while implementing fixed dose combination, new dosage form, and new dosing regimen strategies.

METHODOLOGY

Best Practices, LLC engaged 38 industry professionals from 25 pharmaceutical and biotechnology companies through a benchmarking survey, focus group interviews and round-table discussion. More than sixty percent of the benchmark partners serve at the director or president level.


Industries Profiled:
Health Care; Pharmaceutical; Diagnostic; Biotech; Manufacturing; Consumer Products; Medical Device; Chemical; Biopharmaceutical; Clinical Research; Laboratories


Companies Profiled:
Abbott; Alcon Laboratories; Amgen; Astellas; Bayer; Boehringer Ingelheim; CooperVision; Cubist Pharmaceuticals; Eisai; Galderma; Genentech; Getz Pharma; GlaxoSmithKline ; Grifols; Grünenthal; Medline; Merck; Nektar Therapeutics; Novartis; Novo Nordisk; Roche; Sanofi; Shire; Stiefel; Zimmer Biomet

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.